Magenta therapeutics announces $86.4 million common stock investment from multiple investors

Cambridge, mass.--(business wire)--magenta therapeutics, inc. (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional investors in a private placement. magenta anticipates aggregate gross proceeds from the offering will be $86.4 million, before deducting estimated offering expenses payable
DNTH Ratings Summary
DNTH Quant Ranking